ABBRUPT
Research type
Research Study
Full title
A randomised controlled trial to investigate clinical and cost effectiveness of Amiodarone vs Beta Blockade for new onset atrial fibrillation in ICU - a pragmatic study
IRAS ID
1007930
Contact name
Tony Whitehouse
Contact email
Sponsor organisation
University of Birmingham
Research summary
Patients admitted to Intensive Care Units with a serious illness can go on to develop new onset atrial fibrillation which is a medical emergency. Atrial fibrillation makes the heart less efficient at pumping blood around the body and can result in a very fast heart rate. This can increase the risk of complications such as heart attack and stroke. It is not currently known which is the best treatment for new onset atrial fibrillation in adult patients in the intensive care unit. The ABBRUPT trial is a randomised controlled trial that will compare amiodarone and beta blockade which are both routine treatments used for treating atrial fibrillation. The trial is funded by the National Institute for Health and Care Research and is being run in NHS hospitals throughout the UK. Patients remain in the trial for 90 days. The majority of the data required will be collected from the patient's medical notes. If the patient is discharged from hospital prior to 90 days, a researcher from the hospital will contact the patient by telephone at day 60 and day 90 to complete a brief health questionnaire.
REC name
South Central - Oxford C Research Ethics Committee
REC reference
23/SC/0334
Date of REC Opinion
20 Oct 2023
REC opinion
Further Information Favourable Opinion